Science, Technology and Engineering

Cutts Laboratory

Department of Biochemistry

Publications

Evison BJ, Pastuovic M, Bilardi RA, Forrest RA, Pumuye PP, Sleebs BE, Watson KG, Phillips DR, Cutts SM. (2011) M2, a novel anthracenedione, elicits a potent DNA damage response that can be subverted through checkpoint kinase inhibition to generate mitotic catastrophe. Biochem Pharmacol., Aug 30. [Epub ahead of print].

Tarasenko N, Kessler-Icekson G, Boer P, Inbal A, Schlesinger H, Phillips DR, Cutts SM, Nudelman A, Rephaeli A. (2010) The histone deacetylase inhibitor butyroyloxymethyl diethylphosphate (AN-7) protects normal cells against toxicity of anticancer agents while augmenting their anticancer activity. Invest New Drugs. Sep 23. [Epub ahead of print].

Mansour OC, Evison BJ, Sleebs BE, Watson KG, Nudelman A, Rephaeli A, Buck DP, Collins JG, Bilardi RA, Phillips DR, Cutts SM. (2010) New anthracenedione derivatives with improved biological activity by virtue of stable drug-DNA adduct formation. J Med Chem. 53:6851-6866.

Adnan N, Buck DP, Evison BJ, Cutts SM, Phillips DR, Collins JG. (2010) DNA binding by pixantrone. Org Biomol Chem., 8:5359-5366.

Phillips DR, Swift L, Coldwell K, Spencer D, Bilardi R, Evison B, Mansour O, Nudelman A, Rephaeli A, Koch TH and Cutts SM (2010) Drug-DNA adducts formed by formaldehyde activation of anthracycline and related anti-cancer agents. In “Drug-DNA Adducts: Formation, Detection and Mutagenesis“, Alvarez, E. and Cunha, R (Eds.) Nova Science, NY, ISBN: 978-1-60741-433-9, Chapt 5.

Coldwell K, Cutts SM, Ognibene TJ, Henderson PT, Phillips DR. (2010) Detection of Adriamycin-DNA adducts by accelerator mass spectrometry. Methods Mol Biol., 613:103-118.

Evison BJ, Phillips DR, Cutts SM. (2010) In vitro transcription assay for resolution of drug-DNA interactions at defined DNA sequences. Methods Mol Biol., 613:207-222.

Ugarenko M, Nudelman A, Rephaeli A, Kimura K, Phillips DR, Cutts SM. (2010) ABT-737 overcomes Bcl-2 mediated resistance to doxorubicin-DNA adducts. Biochem Pharmacol. 79:339-349

Ugarenko M, Chan CK, Nudelman A, Rephaeli A, Cutts SM and Phillips DR (2009) Development of pluronic micelle-encapsulated doxorubicin and formaldehyde-releasing prodrugs for localized anticancer chemotherapy, Oncology Res., 17:283-299.

Kimura K, Spencer DM, Bilardi R, Swift LP, Box AJ, Brownlee RT, Cutts SM (2009) Barminomycin, a Model for the Development of New Anthracyclines. Phillips DR. Anticancer Agents Med Chem. 10:70-77.

Evison BJ, Bilardi RA, Chiu FC, Pezzoni G, Phillips DR, Cutts SM (2009) CpG methylation potentiates pixantrone and doxorubicin-induced DNA damage and is a marker of drug sensitivity. Nucleic Acids Res. 37:6355-6370.

Coldwell KE, Cutts SM, Ognibene TJ, Henderson PT, Phillips DR (2008) Detection of Adriamycin-DNA adducts by accelerator mass spectrometry at clinically relevant Adriamycin concentrations. Nucleic Acids Res. 36:e100.

Evison BJ, Chiu F, Pezzoni G, Phillips DR, Cutts SM. (2008) Formaldehyde-activated Pixantrone is a monofunctional DNA alkylator that binds selectively to CpG and CpA doublets. Mol Pharmacol. 74, 184-194.

Levovich I, Nudelman A, Berkovitch G, Swift LP, Cutts SM, Phillips DR, Rephaeli A. (2008) Formaldehyde-releasing prodrugs specifically affect cancer cells by depletion of intracellular glutathione and augmentation of reactive oxygen species. Cancer Chemother Pharmacol. 62, 471-482.

Spencer DM, Bilardi RA, Koch TH, Post GC, Nafie JW, Kimura K, Cutts SM, Phillips DR. (2008) DNA repair in response to anthracycline-DNA adducts: a role for both homologous recombination and nucleotide excision repair. Mutat Res 638, 110-121.

Swift LP, Cutts SM, Nudelman A, Levovich I, Rephaeli A, Phillips DR (2008) The cardio-protecting agent and topoisomerase II catalytic inhibitor sobuzoxane enhances doxorubicin-DNA adduct mediated cytotoxicity. Cancer Chemother Pharmacol.  61, 739-749.

Rephaeli A, Waks-Yona S, Nudelman A, Tarasenko I, Tarasenko N, Phillips DR, Cutts SM, Kessler-Icekson G. (2007) Anticancer prodrugs of butyric acid and formaldehyde protect against doxorubicin-induced cardiotoxicity. Br J Cancer, 96, 1667-1674.

Evison BJ, Mansour O, Menta E, Phillips DR, Cutts SM (2007) Pixantrone can be activated byformaldehyde to generate a potent DNA-adduct forming agent. Nucleic Acids Res.,35, 3581-3589.

Cutts SM, Swift LP, Pillay V,  Forrest RA, Nudelman A, Rephaeli A, Phillips DR (2007) Activation of clinically used anthracyclines by the formaldehyde-releasing prodrug Pivaloyloxymethyl butyrate. Mol. Cancer Therapeutics, 6, 1450-1459.

Engel D, Nudelman A, Levovich I, Gruss-Fischer T, Phillips DR, Cutts SM, Rephaeli A. (2006) Mode of interaction between butyroyloxymethyl-diethyl phosphate (AN-7) and doxorubicin in MCF-7 and resistant MCF-7/Dx cell lines. J. Cancer Res. Clin. Oncol., 132, 673-683.

Rephaeli, A., Entin-Meer, M., Angel, D., Tarasenko, N., Gruss-Fischer, T., Bruachman, I., Phillips, D.R., Cutts, S.M, Haas-Kogan, D. and Nudelman, A. The anti-metastatic activity and selectivity of oral bioavailable butyric acid prodrugs. Investig. New Drugs, 2006. 24, 383-392.

Swift, L.P., Rephaeli, A., Nudelman, A., Phillips, D.R. and Cutts, S.M Doxorubicin-DNA adducts induce a non-topoisomerase II mediated form of cell death. Cancer Res., 2006. 66, 4863-4871.

Cutts SM, Swift LP, Rephaeli A, Nudelman A, Phillips DR. Recent advances in understanding and exploiting the activation of anthracyclines by formaldehyde. Curr Med Chem ACA. 2005. 5(5):431-447.

Cutts SM, Nudelman A, Pillay V, Spencer DMS, Levovich I, Rephaeli A, Phillips DR. Formaldehyde-releasing prodrugs in combination with doxorubicin can overcome cellular drug resistance. Oncol Res. 2005. 15(4):199-213

Cutts SM, Nudelman A, Rephaeli A, Phillips DR The power and potential of doxorubicin-DNA adducts. IUBMB Life. 2005 Feb;57(2):73-81

Rephaeli A, Blank-Porat D, Tarasenko N, Entin-Meer M, Levovich I, Cutts SM, Phillips DR, Malik Z, Nudelman A. In vivo and in vitro antitumor activity of butyroyloxymethyl-diethyl phosphate (AN-7), a histone deacetylase inhibitor, in human prostate cancer. Int J Cancer. 2005 Aug 20;116(2):226-35

Nudelman A, Levovich I, Cutts SM, Phillips DR, Rephaeli A. The role of intracellularly released formaldehyde and butyric acid in the anticancer activity of acyloxyalkyl esters. J Med Chem. 2005 Feb 24;48(4):1042-54

Parker, B.S., Rephaeli, A., Nudelman, A., Phillips, D.R., and Cutts, S.M. Formation of mitoxantrone adducts in human tumor cells: Potentation by AN-9 and DNA methylation. Oncology Res., 2004; 14, 279-290.

Parker BS, Buley T, Evison BJ, Cutts SM, Neumann GM, Iskander MN, Phillips DR. A molecular understanding of mitoxantrone-DNA adduct formation: effect of cytosine methylation and flanking sequences. J Biol Chem. 2004 Apr 30;279(18):18814-23.

Cutts SM, Swift LP, Rephaeli A, Nudelman A, Phillips DR. Sequence specificity of adriamycin-DNA adducts in human tumor cells. Mol Cancer Ther. 2003 Jul;2(7):661-70.

Parker BS, Cutts SM, Nudelman A, Rephaeli A, Phillips DR, Sukumar S. Mitoxantrone mediates demethylation and reexpression of cyclin d2, estrogen receptor and 14.3.3sigma in breast cancer cells. Cancer Biol Ther. 2003 May-Jun;2(3):259-63.

Spencer DM, Cutts SM, Kimura K, Gray PJ, Phillips DR. Detection of labile anthracycline-DNA adducts by real-time PCR. Oncol Res. 2003;13(11):479-89.

Swift LP, Cutts SM, Rephaeli A, Nudelman A, Phillips DR. Activation of adriamycin by the pH-dependent formaldehyde-releasing prodrug hexamethylenetetramine. Mol Cancer Ther. 2003 Feb;2(2):189-98.

Cutts SM, Rephaeli A, Nudelman A, Hmelnitsky I, Phillips DR. Molecular basis for the synergistic interaction of adriamycin with the formaldehyde-releasing prodrug pivaloyloxymethyl butyrate (AN-9). Cancer Res. 2001 Nov 15;61(22):8194-202.

Moufarij MA, Cutts SM, Neumann GM, Kimura K, Phillips DR. Barminomycin functions as a potent pre-activated analogue of Adriamycin. Chem Biol Interact. 2001 Nov 28;138(2):137-53.

Phillips DR, Cutts SM, Cullinane CM, Crothers DM. High-resolution transcription assay for probing drug-DNA interactions at individual drug sites. Methods Enzymol. 2001;340:466-85.

Cutts SM, Parker BS, Swift LP, Kimura KI, Phillips DR. Structural requirements for the formation of anthracycline-DNA adducts. Anticancer Drug Des. 2000 Oct;15(5):373-86.

Saffery R, Wong LH, Irvine DV, Bateman MA, Griffiths B, Cutts SM, Cancilla MR, Cendron AC, Stafford AJ, Choo KH. Construction of neocentromere-based human minichromosomes by telomere-associated chromosomal truncation. Proc Natl Acad Sci U S A. 2001 May 8;98(10):5705-10.

Wheate NJ, Cutts SM, Phillips DR, Aldrich-Wright JR, Collins JG. The binding of [(en)Pt(mu-dpzm)2Pt(en)]4+ to G/C-rich regions of DNA. J Inorg Biochem. 2001 Mar;84(1-2):119-27.

Parker BS, Cutts SM, Phillips DR. Cytosine methylation enhances mitoxantrone-DNA adduct formation at CpG dinucleotides. J Biol Chem. 2001 May 11;276(19):15953-60.

Cullinane C, Cutts SM, Panousis C, Phillips DR. Interstrand cross-linking by adriamycin in nuclear and mitochondrial DNA of MCF-7 cells. Nucleic Acids Res. 2000 Feb 15;28(4):1019-25.

Parker BS, Cutts SM, Cullinane C, Phillips DR. Formaldehyde activation of mitoxantrone yields CpG and CpA specific DNA adducts. Nucleic Acids Res. 2000 Feb 15;28(4):982-90.

Earle E, Saxena A, MacDonald A, Hudson DF, Shaffer LG, Saffery R, Cancilla MR, Cutts SM, Howman E, Choo KH. Poly(ADP-ribose) polymerase at active centromeres and neocentromeres at metaphase. Hum Mol Genet. 2000 Jan 22;9(2):187-94.

Cutts SM, Fowler KJ, Kile BT, Hii LL, O'Dowd RA, Hudson DF, Saffery R, Kalitsis P, Earle E, Choo KH. Defective chromosome segregation, microtubule bundling and nuclear bridging in inner centromere protein gene (Incenp)-disrupted mice. Hum Mol Genet. 1999 Jul;8(7):1145-55.

Saffery R, Irvine DV, Kile BT, Hudson DF, Cutts SM, Choo KH. Cloning, expression, and promoter structure of a mammalian inner centromere protein (INCENP). Mamm Genome. 1999 Apr;10(4):415-8.

For other publications by this author:

This will open a new browser window and connect you in to the NCBI PubMed database. Please close the new window to come back to this page.